For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A051701

Trial Overview

Official Title

Testing The Addition Of A New Anti-Cancer Drug Venetoclax To Usual Chemotherapy For High Grade Cell Lymphomas

Study Purpose

To determine if adding a new drug, venetoclax, to the usual combination of drugs can lower the chance of lymphoma returning or getting worse. Also, to find out if this approach is better or worse than the usual approach for lymphoma.

Diagnosis

MYC/BCL2 Double-hit or double expressing lymphoma

Eligibility

No prior treatment except a single cycle of R-CHOP or DA-EPOCH-R administered prior to enrollment.

No active heart disease or congestive heart failure.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Study Agent: Venetoclax
  • Group 1: chemotherapy called R-CHOP or EPOCH-R (usual approach)
  • Group 2: Usual approach chemotherapy (see above) plus venetoclax
  • Quality of Life questionnaires

Patients will get either treatment for up to 18 months. After treatment is finished, the doctor will continue to follow and watch for side effects for up to 5 years after registered to the study.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase II
Methodist Health System Trial Code
A051701
Related Specialties